TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Prime Medicine, Inc.
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.

Insights
JPMpD   positive

Highlighted as an example of a reliable, long-term investment stock


PRME   positive

Company showed progress in pipeline development, nominated new development candidates, strengthened leadership, maintained financial runway into 2027, and presented promising preclinical data